SMO and medulloblastoma: Of note, administration of the BET inhibitors JQ1 or I-BET-151 suppresses the HH pathway transcriptional output in several HH-driven tumors, such as BCC, medulloblastoma and atypical teratoid rhabdoid tumors, even when the emergence of primary or acquired resistance mechanisms compromises the efficacy of SMO inhibitors (Long et al., 2014; Tang et al., 2014).